Research programme: thyroid hormone receptor alpha antagonists - Karo Pharma
Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Mechanism of Action Thyroid hormone receptor alpha antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 08 Mar 2001 Preclinical development for Arrhythmias in Sweden (Unknown route)